<DOC>
	<DOCNO>NCT01981967</DOCNO>
	<brief_summary>The aim study characterize safety profile IMOJEV® . Primary Objective : - To describe serious adverse event ( SAEs , include adverse event special interest [ AESIs ] ) 60 day administration one dose IMOJEV® . Secondary Objective : - To describe Grade 3 ( severe ) systemic Adverse Events ( AEs ) 30 minute administration one dose IMOJEV® .</brief_summary>
	<brief_title>Post-licensure Safety Study IMOJEV® Thailand</brief_title>
	<detailed_description>Participants age 1 year less 5 year randomize receive one injection IMOJEV® either primary vaccination booster . Safety data collect 60 day IMOJEV® vaccination . The duration subject 's participation trial 60 day .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children require vaccination Japanese encephalitis Children age 9 month le 5 year day inclusion In good general health time inclusion Informed consent form sign dated parent ( ) /legal guardian ( ) Subject parent ( ) /legal guardian ( ) able attend schedule visit additional visit may need do case SAE ( include AESI ) , able comply trial procedures The subject 's parent ( ) /legal guardian ( ) telephone number contact throughout study Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede vaccination Receipt vaccine 4 week precede study vaccination plan receipt vaccine 4 week follow study vaccination Planned participation another clinical trial present trial period Children previously vaccinate live attenuate Japanese encephalitis vaccine CDJEVAX® ( SA14142 LAV ) Contraindications vaccination accord IMOJEV® Summary Product Characteristics ( SmPC ) Identified natural adopt child Investigator employee direct involvement propose study Children receive IMOJEV® primary vaccination study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Japanese encephalitis</keyword>
	<keyword>IMOJEV®</keyword>
	<keyword>Japanese encephalitis chimeric virus vaccine</keyword>
</DOC>